A cannabis extract containing non-psychoactive cannabidiol tested on hard-to-treat epileptic patients cut seizures in half.
The experience of 213 hard-to-treat patients age 2 to 42, including some who were already taking a dozen drugs to fend off seizures, is a promising start for the strawberry-flavored liquid extract [Epidiolex], which may be a potent new therapy for the condition, said lead researcher Orrin Devinsky, director of the New York University Langone Comprehensive Epilepsy Center. The findings released Monday are scheduled to be presented at the American Academy of Neurology's annual meeting on April 22 in Washington.
In other news, the Obama administration, most members of congress, and the DEA steadfastly support marijuana's Schedule 1 controlled substance classification, which is reserved for drugs with "no currently accepted medical use." Their willful disregard for the facts makes them personally culpable for the preventable suffering of over a million people who could be helped by non-psychoactive cannabidiol.